Novartis Ag

Celgene Corporation

Washington University

Novartis Vaccines & Diagnostics, Gmbh

Xoma Technology Ltd.

Hruska, Keith

Fang, Yifu

Sloan, Victor Schorr

Victoria Sung

Hong Yang

Martin Sendzik

Weibo Wang

Savithri Ramurthy

Jiong Lan

James Clifford Sutton

Keith Bruce Pfister

Allan S Wagman

Simon C Ng

Mika Lindvall

Marion Wiesmann

Elizabeth J Mieuli

Anu Sharma

Liana M Klivansky

William Lenahan

Susan Kaufman

William Allen Smith

Randall Stevens

Keith A Hruska

William Michael Kavanaugh

William H Smith

Yifu Fang

Olivier Hermine

Maria Cappellini

Victor Schorr Sloan

Lea Aukerman

Michael Dussiot

Thiago Trovati Maciel

Aurelie Fricot

Mika K Lindvall

William P Lenahan

Ivan Cruz Moura

Rajesh Chopra

William Smith

Lea Auckerman

Provided herein are methods of treating beta-thalassemia in a subject comprising administering to the subject an activin type II receptor (ActRII) signaling inhibitor (e.g., an activin ligand trap) and utilizing one or more in vitro cell culture methods provided herein in (i) selection of the subject to be treated according to the methods provided herein; and/or (ii) monitoring of the subject being treated according to the methods provided herein.

In vitro cell culture methods for beta-thalassemia using activin type II receptor ligand traps

Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.

Activin-ActRII antagonists and uses for treating bone and other disorders

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling

M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in or remodeling in a subject afflicted with an osteoblastic or osteolytic disease.

M-CSF-specific monoclonal antibody and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Victoria Sung